ArticleAJPM focus2026
Trends in Buprenorphine and Methadone Dispensing Among Medicare Advantage and Commercial Enrollees, 2019-2024.
Article in AJPM focus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Introduction: Despite the existence of effective medications for opioid use disorder, including methadone and buprenorphine, overdose deaths remain high. In 2020, Medicare began covering methadone for the treatment of opioid use disorder; separate federal policy changes expanded medications for opioid use disorder access through telemedicine in response to the COVID-19 pandemic. However, little is known about national trends in methadone and buprenorphine dispensing across commercial and Medicare Advantage payers, especially by patient characteristics. Methods: A retrospective repeated cross-sectional study was conducted using 2019-2024 data from Optum's deidentified Clinformatics Data Mart Database to examine quarterly methadone and buprenorphine dispensing rates per 100,000 enrollees diagnosed with opioid use disorder. Rates were stratified by insurance type (commercial versus Medicare Advantage), age, and dual eligibility status. Joinpoint regression identified statistically supported trend inflection points and annual percentage changes per segment. Results: Among opioid use disorder-diagnosed enrollees, Medicare Advantage methadone rates rose from 624 to 5,462 per 100,000 between 2020 Quarter 1 and 2024 Quarter 2 (average annual percentage change of +104.6% per year), whereas commercial methadone rates increased from 3,552 to 6,821 per 100,000 (average annual percentage change of +23.9% per year) during the same period. Medicare Advantage buprenorphine rates increased steadily (average annual percentage change of +20.7% per year), whereas commercial buprenorphine rates peaked in 2022 and declined at -20.0% per year after 2023 Quarter 2. Dually eligible Medicare Advantage enrollees aged <65 years had the highest medications for opioid use disorder dispensing rates throughout. Conclusions: Methadone dispensing increased substantially among Medicare Advantage enrollees with opioid use disorder after 2020, particularly among dually eligible beneficiaries aged <65 years. The decline in commercial buprenorphine dispensing after 2022 warrants further investigation. Tailored efforts may be needed to close payer-related treatment gaps and support broader medications for opioid use disorder access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.